Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma

BMC Immunology

Michael Linnebacher¹  Ernst Klar¹  Sven Eisold¹  Christina S Mullins¹ 

[1] Department of General, Thoracic, Vascular and Transplantation Surgery, Section Molecular Oncology and Immunotherapy, University of Rostock, Schillingallee 35, 18055 Rostock, GERMANY

关键词: reverse immunology;    immunotherapy;    T cell epitopes;    colorectal cancer;    tumor antigens;    therapy resistance;    Multidrug resistance;   

Others  :  1077999
DOI  :  10.1186/1471-2172-12-38

 received in 2011-04-03, accepted in 2011-07-10,  发布年份 2011

【 摘 要 】

Background

Multidrug resistance (MDR) is a clinically, highly relevant phenomenon. Under chemotherapy many tumors show an increasing resistance towards the applied substance(s) and to a certain extent also towards other agents. An important molecular cause of this phenomenon is an increased expression of transporter proteins. The functional relationship between high expression levels and chemotherapy resistance makes these MDR and MRP (MDR related protein) proteins to interesting therapeutic targets. We here wanted to systematically analyze, whether these proteins are tumor specific antigens which could be targeted immunologically.

Results

Using the reverse immunology approach, 30 HLA-A2.1 restricted MDR and MRP derived peptides (MDP) were selected. Stimulated T cell lines grew well and mainly contained activated CD8⁺ cells. Peptide specificity and HLA-A2.1 restriction were proven in IFN-γ-ELISpot analyses and in cytotoxicity tests against MDP loaded target cells for a total of twelve peptides derived from MDR-1, MDR-3, MRP-1, MRP-2, MRP-3 and MRP-5. Of note, two of these epitopes are shared between MDR-1 and MDR-3 as well as MRP-2 and MRP-3. However, comparably weak cytotoxic activities were additionally observed against HLA-A2.1⁺ tumor cells even after upregulation of MDR protein expression by in vitro chemotherapy.

Conclusions

Taken together, these data demonstrate that human T cells can be sensitised towards MDPs and hence, there is no absolute immunological tolerance. However, our data also hint towards rather low endogenous tumor cell processing and presentation of MDPs in the context of HLA-A2.1 molecules. Consequently, we conclude that MDR and MRP proteins must be considered as weak tumor specific antigens-at least for colorectal carcinoma. Their direct contribution to therapy-failure implies however, that it is worth to further pursue this approach.

【 授权许可】

   
2011 Mullins et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
• [2]Krishna R, Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11(4):265-83.
• [3]Johnstone RW, Ruefli AA, Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000, 25(1):1-6.
• [4]Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009, 14(1):3-9.
• [5]Yamanaka R: Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009, 32(3):265-73. discussion 273
• [6]Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000, 60(4):829-33.
• [7]Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M: High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010, 95(7):1191-7.
• [8]Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113(26):6541-8.
• [9]Mano M, Humblet Y: Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 2008, 5(7):415-25.
• [10]Gutierrez C, Schiff R: HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011, 135(1):55-62.
• [11]Wu Y, Wang L, Zhang Y: Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy. Cell Mol Immunol 2004, 1(5):351-6.
• [12]O'Neill DW, Adams S, Bhardwaj N: Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104(8):2235-46.
• [13]Vauleon E, Avril T, Collet B, Mosser J, Quillien V: Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010., 2010pii: 689171
• [14]Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R: Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006, 24(31):5060-9.
• [15]Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J: Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009, 15(7):2507-13.
• [16]Gilboa E: The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001, 2(9):789-92.
• [17]Kessler JH, Melief CJ: Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007, 21(9):1859-74.
• [18]Schietinger A, Philip M, Schreiber H: Specificity in cancer immunotherapy. Semin Immunol 2008, 20(5):276-85.
• [19]Kuan CT, Wakiya K, Herndon JE, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD: MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010, 10:468. BioMed Central Full Text
• [20]Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD: Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 2010, 127(3):598-611.
• [21]Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M: Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 2001, 93(1):6-11.
• [22]Hans-Georg Rammensee, Jutta Bachmann, Niels Nikolaus Emmerich, Oskar Alexander Bachor, Stefan Stevanovic: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
• [23]Linnebacher M, Wienck A, Boeck I, Klar E: Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol 2010, 2010:841451.
• [24]Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I: Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 2004, 34:201-3.
• [25]Pals G, Pindolia K, Worsham MJ: A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. Mol Diagn 1999, 4:241-6.
• [26]Vonderheide RH, Hahn WC, Schultze JL, Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-9.
• [27]Huls M, Russel FG, Masereeuw RJ: The role of ATP binding cassette transporters in tissue defense and organ regeneration. Pharmacol Exp Ther 2009, 328(1):3-9.
• [28]Callaghan R, Crowley E, Potter S, Kerr ID: P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008, 48(3):365-78.
• [29]Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K: Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 2009, 27(9):901-8.
• [30]Mannarini L, Bertino G, Morbini P, Villa C, Benazzo M: Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital 2007, 27(4):173-80.
• [31]Tan BT, Park CY, Ailles LE, Weissman IL: The cancer stem cell hypothesis: a work in progress. Lab Invest 2006, 86(12):1203-7.
• [32]Correa I, Plunkett T: Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 2001, 3(6):399-403. BioMed Central Full Text
• [33]Deininger M, Buchdunger E, Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105(7):2640-53.
• [34]Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC: Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006, 55(10):1294-8.
• [35]Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002, 21(4):674-9.
• [36]Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K: Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001, 61(17):6459-66.